Hepatocellular Carcinoma (HCC) Clinical Trials

109 recruitingLast updated: June 17, 2026

There are 109 actively recruiting hepatocellular carcinoma (hcc) clinical trials across 28 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Shanghai, Shanghai Municipality, China, Guangzhou, Guangdong, China, Hangzhou, Zhejiang, China. Updated daily from ClinicalTrials.gov.


Hepatocellular Carcinoma (HCC) Trials at a Glance

109 actively recruiting trials for hepatocellular carcinoma (hcc) are listed on ClinicalTrialsFinder across 6 cities in 28 countries. The largest study group is Phase 2 with 41 trials, with the heaviest enrollment activity in Shanghai, Guangzhou, and Hangzhou. Lead sponsors running hepatocellular carcinoma (hcc) studies include Fudan University, Seoul National University Hospital, and Zhejiang University.

Browse hepatocellular carcinoma (hcc) trials by phase

Treatments under study

About Hepatocellular Carcinoma (HCC) Clinical Trials

Looking for clinical trials for Hepatocellular Carcinoma (HCC)? There are currently 96 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hepatocellular Carcinoma (HCC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hepatocellular Carcinoma (HCC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 109 trials

Recruiting
Phase 1Phase 2

A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC

Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Huahui Health30 enrolled21 locationsNCT07547553
Recruiting

mSEPT9 Biomarker for Predicting Hepatocellular Carcinoma Occurrence in Patients With Cirrhosis

CirrhosisHepatocellular Carcinoma (HCC)Epigenomics+1 more
Central Hospital, Nancy, France400 enrolled1 locationNCT06778317
Recruiting

Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning

Liver surgeryHepatocellular Carcinoma (HCC)Adjuvant Chemoradiotherapy+3 more
Second Affiliated Hospital, School of Medicine, Zhejiang University11,000 enrolled1 locationNCT07417800
Recruiting
Phase 2

Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC

Hepatocellular Carcinoma (HCC)
Shunda Du32 enrolled1 locationNCT07639138
Recruiting
Phase 1

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Endometrial CancerRenal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)+1 more
Compass Therapeutics70 enrolled5 locationsNCT07419841
Recruiting

Liver Cancer Registry Platform

CholangiocarcinomaHepatocellular Carcinoma (HCC)
iOMEDICO AG1,000 enrolled1 locationNCT04510740
Recruiting

Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)

Hepatocellular Carcinoma (HCC)
City of Hope Medical Center600 enrolled1 locationNCT07265271
Recruiting
Phase 1

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Advanced Solid TumorsEwing SarcomaHepatocellular Carcinoma (HCC)+1 more
SEED Therapeutics, Inc.171 enrolled6 locationsNCT07197554
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb198 enrolled59 locationsNCT07291076
Recruiting
Not Applicable

Improving the Use of Immunotherapy to Treat Liver Cancer

Hepatocellular Carcinoma (HCC)
Universitaire Ziekenhuizen KU Leuven300 enrolled4 locationsNCT07623265
Recruiting
Phase 2

Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus

Hepatocellular Carcinoma (HCC)Portal Vein Tumor Thrombus
First Hospital of China Medical University38 enrolled1 locationNCT07483359
Recruiting
Phase 1

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 2

Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy

Hepatocellular Carcinoma (HCC)
CHA University80 enrolled1 locationNCT07493668
Recruiting
Phase 1

To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors

Pancreatic Ductal Adenocarcinoma (PDAC)Hepatocellular Carcinoma (HCC)Gastric Cancer (GC)+1 more
Shenzhen Xinhe Biomedical48 enrolled2 locationsNCT07594964
Recruiting
Not Applicable

18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors

Breast CancerColorectal, CancerPancreatic Cancer+11 more
Peking University First Hospital200 enrolled1 locationNCT07557225
Recruiting
Phase 1

An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma (HCC)GPC3 Positive Hepatocellular Carcinoma
Guangzhou FineImmune Biotechnology Co., LTD.15 enrolled1 locationNCT07493044
Recruiting
Not Applicable

Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN

Neuroendocrine TumorsHepatocellular Carcinoma (HCC)Intrahepatic Cholangiocarcinoma (Icc)
Nantes University Hospital60 enrolled2 locationsNCT06735560
Recruiting
Phase 2

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)
Tianjin Medical University Cancer Institute and Hospital30 enrolled1 locationNCT07012798
Recruiting
Not Applicable

Computer Guided Microwave Liver Ablation

Hepatocellular Carcinoma (HCC)
NE Scientific INC84 enrolled2 locationsNCT07226869
Recruiting
Phase 2

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)
Tongji Hospital94 enrolled1 locationNCT07413354